Details for Patent: 7,491,725
✉ Email this page to a colleague
Which drugs does patent 7,491,725 protect, and when does it expire?
Patent 7,491,725 protects SPRYCEL and is included in one NDA.
Protection for SPRYCEL has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-seven patent family members in twenty-nine countries.
Summary for Patent: 7,491,725
Title: | Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
Abstract: | The invention relates to processes for preparing compounds having the formula, ##STR00001## and crystalline forms thereof, wherein Ar is aryl or heteroaryl, L is an optional alkylene linker, and R.sub.2, R.sub.3, R.sub.4, and R.sub.5, are as defined in the specification herein, which compounds are useful as kinase inhibitors, in particular, inhibitors of protein tyrosine kinase and p38 kinase. |
Inventor(s): | Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Pennington, NJ) |
Assignee: | Bristol-Myers Squibb Company (Princeton, NJ) |
Application Number: | 11/192,867 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 7,491,725 |
Patent Claim Types: see list of patent claims | Compound; Composition; Process; |
Drugs Protected by US Patent 7,491,725
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-001 | Jun 28, 2006 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-002 | Jun 28, 2006 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-003 | Jun 28, 2006 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Bristol Myers Squibb | SPRYCEL | dasatinib | TABLET;ORAL | 021986-005 | Oct 28, 2010 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,491,725
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 047533 | ⤷ Sign Up | |||
Argentina | 053984 | ⤷ Sign Up | |||
Austria | E453630 | ⤷ Sign Up | |||
Australia | 2005212405 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |